Physician profile
Mark A Kaplan
NPI 1215925052
$1,004.79
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $135 · 2021: $18.67 · 2022: $31.33 · 2023: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $150.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $125.55 | 2019-2020 | |
| Intuitive Surgical, INC. | $124.73 | 2023 | Da Vinci Surgical System |
| Puma Biotechnology, INC. | $116.78 | 2019-2020 | |
| Eisai INC. | $94.82 | 2019 | |
| Tesaro, INC. | $88.00 | 2019 | |
| Foundation Medicine, INC. | $82.98 | 2019-2020 | |
| Celgene Corporation | $72.83 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $65.81 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.66 | 2019 | |
| Ethicon US, LLC | $26.23 | 2023 | Surgicel Nu-Knit, Enseal |
| Jazz Pharmaceuticals INC. | $22.12 | 2020 | |
| Siemens Medical Solutions USA, INC. | $18.67 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.79 | 2022 | |
| Merck Sharp & Dohme LLC | $16.78 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $16.65 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho-Clinical Diagnostics, INC. | $14.54 | 2022 | |
| Abbvie INC. | $13.82 | 2020 | |
| Genzyme Corporation | $12.90 | 2019 | |
| Spectrum Pharmaceuticals INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.